| Primary |
| Prostate Cancer |
33.4% |
| Product Used For Unknown Indication |
29.6% |
| Drug Use For Unknown Indication |
14.3% |
| Prostate Cancer Metastatic |
10.5% |
| Antiandrogen Therapy |
1.7% |
| Prophylaxis |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Prostatic Specific Antigen Increased |
1.3% |
| Breast Cancer |
0.9% |
| Neoplasm Prostate |
0.9% |
| Hypertension |
0.8% |
| Radical Prostatectomy |
0.6% |
| Condition Aggravated |
0.4% |
| Diabetes Mellitus |
0.4% |
| Metastases To Bone |
0.4% |
| Osteoporosis Prophylaxis |
0.4% |
| Ovarian Disorder |
0.4% |
| Radiotherapy |
0.4% |
| Type 2 Diabetes Mellitus |
0.4% |
| Adjuvant Therapy |
0.2% |
|
| Prostate Cancer |
25.4% |
| Death |
13.9% |
| Prostatic Specific Antigen Increased |
6.6% |
| Renal Failure |
5.7% |
| Urinary Retention |
4.9% |
| Bronchial Carcinoma |
4.1% |
| Myocardial Infarction |
4.1% |
| Bladder Cancer |
3.3% |
| Cardiac Death |
3.3% |
| Cerebrovascular Accident |
3.3% |
| Pneumonia |
3.3% |
| Diplegia |
2.5% |
| Dyspnoea |
2.5% |
| Gait Disturbance |
2.5% |
| Injection Site Necrosis |
2.5% |
| Injection Site Swelling |
2.5% |
| Metastases To Bone |
2.5% |
| Papilloedema |
2.5% |
| Prostate Cancer Metastatic |
2.5% |
| Pulmonary Embolism |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
32.9% |
| Prostate Cancer |
25.3% |
| Prostatic Specific Antigen Increased |
6.2% |
| Drug Use For Unknown Indication |
5.5% |
| Prophylaxis |
4.8% |
| Prostate Cancer Metastatic |
3.4% |
| Radical Prostatectomy |
3.4% |
| Antiandrogen Therapy |
2.7% |
| Metastases To Bone |
2.7% |
| Radiotherapy |
2.7% |
| Condition Aggravated |
2.1% |
| Chronic Obstructive Pulmonary Disease |
1.4% |
| Hypertension |
1.4% |
| Ovarian Disorder |
1.4% |
| Adjuvant Therapy |
0.7% |
| Breast Cancer |
0.7% |
| Diabetes Mellitus |
0.7% |
| Hypothyroidism |
0.7% |
| Neoadjuvant Therapy |
0.7% |
| Osteoporosis |
0.7% |
|
| Diplegia |
10.3% |
| Prostate Cancer |
10.3% |
| Disease Progression |
6.9% |
| Haemoglobin Decreased |
6.9% |
| Hyperuricaemia |
6.9% |
| Incontinence |
6.9% |
| Rectal Cancer |
6.9% |
| Bronchial Carcinoma |
3.4% |
| Constipation |
3.4% |
| Coronary Artery Disease |
3.4% |
| Exercise Tolerance Decreased |
3.4% |
| Femur Fracture |
3.4% |
| Hemiparesis |
3.4% |
| Hypopharyngeal Cancer |
3.4% |
| Inappropriate Schedule Of Drug Administration |
3.4% |
| Injection Site Abscess |
3.4% |
| Metastases To Pelvis |
3.4% |
| Oropharyngeal Cancer |
3.4% |
| Pneumonitis |
3.4% |
| Pulmonary Embolism |
3.4% |
|
| Concomitant |
| Prostate Cancer Metastatic |
19.0% |
| Prostate Cancer |
14.5% |
| Metastases To Bone |
11.1% |
| Product Used For Unknown Indication |
9.7% |
| Hypertension |
8.0% |
| Cancer Pain |
6.3% |
| Hormone Therapy |
6.3% |
| Prophylaxis |
6.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.7% |
| Drug Use For Unknown Indication |
3.1% |
| Hormone-refractory Prostate Cancer |
2.0% |
| Hormone Replacement Therapy |
1.7% |
| Performance Status Decreased |
1.4% |
| Renal Cell Carcinoma Stage Unspecified |
1.4% |
| Asthma |
1.1% |
| Hypercholesterolaemia |
1.1% |
| Coronary Artery Disease |
0.9% |
| Embolic Stroke |
0.9% |
| Hyperlipidaemia |
0.9% |
| Hyperparathyroidism Secondary |
0.9% |
|
| Neoplasm Malignant |
17.6% |
| Atrioventricular Block Complete |
9.8% |
| Tooth Extraction |
9.8% |
| Osteonecrosis |
7.8% |
| Hospitalisation |
5.9% |
| Anaemia |
3.9% |
| Cerebral Ischaemia |
3.9% |
| Osteonecrosis Of Jaw |
3.9% |
| Renal Failure |
3.9% |
| Stomatitis |
3.9% |
| Tooth Fracture |
3.9% |
| Tooth Infection |
3.9% |
| Transient Ischaemic Attack |
3.9% |
| Vomiting |
3.9% |
| X-ray Abnormal |
3.9% |
| Anaphylactic Shock |
2.0% |
| Cerebrovascular Accident |
2.0% |
| Constipation |
2.0% |
| Diarrhoea |
2.0% |
| Diverticulitis |
2.0% |
|
